Lataa...
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/d, with dose escalation up to 1000 mg/d over 60 days). The median age was 66 years and 71% were males. Study participants received a median of 2 (range 1–7) prior...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3928100/ https://ncbi.nlm.nih.gov/pubmed/19373657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902777467 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|